195 related articles for article (PubMed ID: 16628753)
1. Identification by 19F NMR of traditional Chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity.
Tarragó T; Frutos S; Rodriguez-Mias RA; Giralt E
Chembiochem; 2006 May; 7(5):827-33. PubMed ID: 16628753
[TBL] [Abstract][Full Text] [Related]
2. The natural product berberine is a human prolyl oligopeptidase inhibitor.
Tarrago T; Kichik N; Seguí J; Giralt E
ChemMedChem; 2007 Mar; 2(3):354-9. PubMed ID: 17295371
[TBL] [Abstract][Full Text] [Related]
3. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.
Tarragó T; Kichik N; Claasen B; Prades R; Teixidó M; Giralt E
Bioorg Med Chem; 2008 Aug; 16(15):7516-24. PubMed ID: 18650094
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous (19)F NMR screening of prolyl oligopeptidase and dipeptidyl peptidase IV inhibitors.
Kichik N; Tarragó T; Giralt E
Chembiochem; 2010 May; 11(8):1115-9. PubMed ID: 20397181
[TBL] [Abstract][Full Text] [Related]
5. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
[TBL] [Abstract][Full Text] [Related]
6. Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase.
Gorrão SS; Hemerly JP; Lima AR; Melo RL; Szeltner Z; Polgár L; Juliano MA; Juliano L
Peptides; 2007 Nov; 28(11):2146-54. PubMed ID: 17904692
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010.
López A; Tarragó T; Giralt E
Expert Opin Ther Pat; 2011 Jul; 21(7):1023-44. PubMed ID: 21539473
[TBL] [Abstract][Full Text] [Related]
8. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
[TBL] [Abstract][Full Text] [Related]
9. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.
Venäläinen JI; Garcia-Horsman JA; Forsberg MM; Jalkanen A; Wallén EA; Jarho EM; Christiaans JA; Gynther J; Männistö PT
Biochem Pharmacol; 2006 Feb; 71(5):683-92. PubMed ID: 16405869
[TBL] [Abstract][Full Text] [Related]
10. Slow-binding human serine racemase inhibitors from high-throughput screening of combinatorial libraries.
Dixon SM; Li P; Liu R; Wolosker H; Lam KS; Kurth MJ; Toney MD
J Med Chem; 2006 Apr; 49(8):2388-97. PubMed ID: 16610782
[TBL] [Abstract][Full Text] [Related]
11. A new side opening on prolyl oligopeptidase revealed by electron microscopy.
Tarragó T; Martín-Benito J; Sabidó E; Claasen B; Madurga S; Gairí M; Valpuesta JM; Giralt E
FEBS Lett; 2009 Oct; 583(20):3344-8. PubMed ID: 19782684
[TBL] [Abstract][Full Text] [Related]
12. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
[TBL] [Abstract][Full Text] [Related]
13. On the role of prolyl oligopeptidase in health and disease.
García-Horsman JA; Männistö PT; Venäläinen JI
Neuropeptides; 2007 Feb; 41(1):1-24. PubMed ID: 17196652
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
[TBL] [Abstract][Full Text] [Related]
15. Traditional Chinese medicines with caspase-inhibitory activity.
Fattorusso R; Frutos S; Sun X; Sucher NJ; Pellecchia M
Phytomedicine; 2006 Jan; 13(1-2):16-22. PubMed ID: 16360928
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
Tran T; Quan C; Edosada CY; Mayeda M; Wiesmann C; Sutherlin D; Wolf BB
Bioorg Med Chem Lett; 2007 Mar; 17(5):1438-42. PubMed ID: 17174090
[TBL] [Abstract][Full Text] [Related]
17. Polyfluorinated amino acids for sensitive 19F NMR-based screening and kinetic measurements.
Papeo G; Giordano P; Brasca MG; Buzzo F; Caronni D; Ciprandi F; Mongelli N; Veronesi M; Vulpetti A; Dalvit C
J Am Chem Soc; 2007 May; 129(17):5665-72. PubMed ID: 17417847
[TBL] [Abstract][Full Text] [Related]
18. [Research advances in coordination chemistry of traditional Chinese medicine].
Li YH; Lu XY; Liu X; Liu Y
Zhongguo Zhong Yao Za Zhi; 2006 Aug; 31(16):1309-13. PubMed ID: 17061546
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity improvement in 19F NMR-based screening experiments: theoretical considerations and experimental applications.
Dalvit C; Mongelli N; Papeo G; Giordano P; Veronesi M; Moskau D; Kümmerle R
J Am Chem Soc; 2005 Sep; 127(38):13380-5. PubMed ID: 16173772
[TBL] [Abstract][Full Text] [Related]
20. Characterization of membrane-bound prolyl endopeptidase from brain.
Tenorio-Laranga J; Venäläinen JI; Männistö PT; García-Horsman JA
FEBS J; 2008 Sep; 275(17):4415-27. PubMed ID: 18657187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
